Biodesix commended the Centers for Medicare & Medicaid Services (CMS) for publishing preliminary 2018 rates for clinical diagnostic laboratory tests.
A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test
Interim study results: Veristrat testing impacts lung cancer treatment in all stages; early stage patients get significantly different treatments after test
Biodesix is presenting two talks on DNA process optimization at the Cancer Genomics Consortium
Peer reviewed journal: VeriStrat test identifies patients with squamous cell lung cancer who are more likely to have improved survival on afatanib (Gilotrif)
The GeneStrat test, a liquid biopsy test used in lung cancer, has earned approval from NY State-CLEP, along with several other demanding certifications.
The Positive Bioscience agreement will make GeneStrat and VeriStrat tests available in India
A new study demonstrates that VeriStrat can help physicians improve quality care and cancer care planning for patients with advanced lung cancer.
New Biodesix data on liquid biopsy genomic tests, evaluation of biological processes underlying mass spectrometry proteomic assays of human serum
VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).